ARTICLE;
BINDING AFFINITY;
CLINICAL STUDY;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG BINDING SITE;
DRUG DESIGN;
DRUG MARKETING;
DRUG MECHANISM;
DRUG POTENCY;
DRUG SELECTIVITY;
DRUG TARGETING;
HUMAN;
STRUCTURE ACTIVITY RELATION;
X RAY CRYSTALLOGRAPHY;
Thienothiopyran-2-sulfonamides: Nove topically active carbonic anhydrase for the treatment of glaucoma
Baldwin JJ et al (1989) Thienothiopyran-2-sulfonamides: Nove topically active carbonic anhydrase for the treatment of glaucoma. Journal of Medicinal Chemistry 32:2510-2513.
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities
Kim KS et al (2002) Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities. Journal of Medicinal Chemistry 45:3905-3927.
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2]pyrimidine-6-acrylamides bearing additional solubilizing functions
Smaill JB et al (2000) Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2]pyrimidine-6-acrylamides bearing additional solubilizing functions. Journal of Medicinal Chemistry 43:1380-1397.
Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308
Hoekstra WJ et al (1999) Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. Journal of Medicinal Chemistry 42:5254-5265.
Evolution of anti-HIV drug candidates. Part 3: Diarylprimidine (DAPY) analogues
Ludovici HL et al (2001) Evolution of anti-HIV drug candidates. Part 3: Diarylprimidine (DAPY) analogues. Bioorganic and Medicinal Chemistry Letters 11:22335.
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
Sham HL et al (1998) ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobal Agents and Chemotherapy 42:3218-3224.
Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV Protase Inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class
Turner SR et al (1998) Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV Protase Inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. Journal of Medicinal Chemistry 41:3467-3476.
Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5′-monophosphate dehydrogenase inhibitor
Jain J et al (2002) Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5′-monophosphate dehydrogenase inhibitor. Journal of Pharmacology and Experimental Therapeutics 302:1272-1277.
A selective peroxisome proliferator-activated receptor agonist promotes reverse cholesterol transport
Oliver WR et al (2002) A selective peroxisome proliferator-activated receptor agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Science USA 98:5306-5311.
Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor - BCX-1777
Bantia S et al (2003) Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor - BCX-1777. International Immunopharmacology 3:879-887.
SU6668 is a potent antiagiogenic and antitumor agent that induces regression of established tumors
Laird AD et al (2000) SU6668 is a potent antiagiogenic and antitumor agent that induces regression of established tumors. Cancer Research 60:4152-4160.
Structure-based design of aliskiren, a novel orally effective renin inhibitor
Wood JM et al (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochemistry and Biophysics Research Communications 308:698-705.
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides
Burgey CS et al (2003) Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides. Bioorganic and Medicinal Chemistry Letters 13:1353-1357.
Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines
Burgey CS et al (2003) Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines. Journal of Medicinal Chemistry 46:461-473.
